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Aims: To investigate the perspectives and experiences of service providers regarding 
provision of take-home naloxone to people who use opioids in Victoria, Australia. 
Methods: Content analysis of qualitative semi-structured interviews with 15 service providers 
who are either involved with take-home naloxone programs or whose work brings them in 
contact with people who use opioids. 
Findings: Statements about take-home naloxone were universally positive. Both direct and 
indirect benefits of take-home naloxone were described. Alongside potential reductions in 
opioid overdose-related harms, service providers highlighted the empowering effects of 
providing people who use opioids with take-home naloxone. No significant risks were 
described. Service providers supported the expansion of naloxone availability, but also 
identified several intertwined barriers to doing so. Key among these were costs, current 
regulations and scheduling, availability of prescribers and stigma related to illicit and 
injecting drug use. 
Conclusions: Expanding the availability of naloxone is a key component of strategies to 
reduce harms associated with opioid overdose. Our article provides Australian evidence of 
the successful operational implementation of peer-to-peer THN delivery within a range of 
drug primary health services and needle syringe programs. Further research is required to 
better understand the implications of and impediments to scale-up of this potentially life-
saving public health intervention.  
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Benefits and barriers to expanding the availability of take-home naloxone in Australia: 




Opioid overdose remains a significant global public health concern (World Health 
Organization, 2014). North America, the United Kingdom and other parts of Europe are 
presently experiencing increases in rates of heroin and other opioid overdose (Chen, 
Hedegaard and Warner, 2015; EMCCDA, 2015a; Jones et al., 2015; Wise, 2015) and 
epidemiological data suggest rates of opioid overdose may be increasing in Australia. 
Recently the Australian National Coronial Information System (NCIS) reported on all opioid 
deaths (accidental and intentional) reported to an Australian coroner from 2007 to 2011. In 
this five year period, 4,102 opioid-related deaths were reported. Of these opioid-related 
deaths, heroin was the opioid most frequently involved (27% of the deaths), followed by 
methadone (21%) and oxycodone (19%). There was a 14 per cent increase in the number of 
opioid-related deaths between 2007 to 2010 (National Coronial Information System, 2014). 
 
Naloxone, an opioid-antagonist, has been used for over 40 years in emergency medicine to 
reverse the effects of opioids (Lenton et al., 2015). Over the last two decades, measures have 
been implemented to extend the availability of naloxone to non-medical personnel who may 
witness opioid overdose. These take-home naloxone (THN) programs typically involve 
people who use opioids and their partners, families and friends. They have been implemented 
in jurisdictions in north America, the United Kingdom, Europe, Asia and Australia to reduce 
opioid overdose-related harm (Coffin, Sherman and Curtis, 2010; Curtis and Guterman, 
2009;; Lenton et al., 2015; Strang et al., 2014). A substantial body of evidence has now 
accumulated demonstrating that providing THN to people who use opioids and other 
potential overdose witnesses is a safe and effective intervention which can result in 
successful opioid overdose reversals (Clark, Wilder and Winstanley, 2014; EMCDDA, 
2015b; Giglio, Li and DiMaggio, 2015; Lenton et al., 2015; Mueller et al., 2015; Strang et al., 
2014). Mathematical modelling highlights that distributing THN to heroin consumers is a 
cost-effective overdose prevention strategy (Coffin and Sullivan, 2013) while recent research 
from Scotland provides the first population-level evidence of the effectiveness of THN in 
reducing overdose deaths among people recently released from prison (Bird, McAuley, Perry 
and Hunter, 2016).  
  
Most THN initiatives have been implemented within specialist drug services such as needle 
and syringe programs (NSPs), harm reduction programs and drug treatment services 
(McAuley et al., 2012; Mueller et al., 2015). International research suggests low awareness of 
THN and inconsistent levels of support for THN among health professionals (e.g., General 
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Practitioners, pain specialists, emergency department clinicians, pharmacists) and first 
responders (paramedics, police) working outside specialist drug services (Banta-Green et al., 
2013; Beletsky et al., 2006; Binswanger et al., 2015; Matheson et al. 2014; Zaller et al., 
2013). According to Mueller et al., (2015) potential barriers to expansion of THN to wider 
settings include: health professionals’ concern that non-medical personnel would be unable to 
appropriately recognise an opioid overdose and administer naloxone; a ‘moral hazard’ 
concern that THN would encourage increased opioid consumption as having naloxone 
available would provide a ‘safety net’; medico-legal concerns; and the cost of naloxone to 
patients. International research also suggests that the stigma attaching to drug use and 
corresponding negative attitudes to people who use or inject drugs may constitute a barrier to 
expansion of THN from specialist drug services to wider settings (Beletsky et al., 2006; 
Matheson et al., 2014). This literature also indicates that logistical issues such as medical 
provider time and resources, may serve as impediments to expansion of THN (Binswanger et 
al., 2015; Matheson et al., 2014). 
 
In Australia, drug user representatives, service providers and researchers have advocated for 
the implementation of THN programs since the mid-1990s (Lenton and Hargreaves, 2000; 
Strang et al., 2014). However, it was only in April 2012 that the first THN program 
commenced in Australia in the Australian Capital Territory (Lancaster and Ritter, 2014; 
Olsen et al., 2015). Since this time, THN programs have been established in all but two 
Australian jurisdictions (Dietze et al., 2015; Lenton et al., 2015). In Australia, naloxone has 
been listed as a prescription-only medicine but will be available over the counter from 
February 2016 (Lenton, Dietze and Jauncey, 2015). All current Australian THN programs 
include a training component (overdose recognition and response and naloxone 
administration) and provide a mechanism for naloxone prescription and dispensation. These 
initiatives have developed via collaborations between diverse stakeholders and vary 
considerably in size and the mechanisms for prescription and dispensing. Programs also vary 
by training delivery models, including peer-to-peer training, nurse and physician training, as 
well as delivery by drug or other health and welfare workers (Chronister et al., 2015; 
Lancaster and Ritter, 2014; Lenton et al., 2015; Olsen et al., 2015). 
 
In the Australian state of Victoria, two parallel THN strategies have been implemented. One 
strategy comprises a peer-based THN program led by Victoria’s drug user organisation, 
Harm Reduction Victoria (HRV), in collaboration with specialist drug-related primary health 
services and needle syringe programs (NSP). This initiative commenced in August 2013. The 
HRV peer-to-peer program primarily involves training small groups (5-10 people) of people 
who use opioids in opioid overdose recognition and response, including administration of 
naloxone. The THN training component is designed and delivered by the HRV peer educator. 
The collaborating services recruit participants for training, host the group training sessions 
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and provide access to a General Practitioner (GP) for prescription of naloxone. Duration of 
group training sessions ranges from one to two hours. The HRV peer educator also 
opportunistically conducts brief (15-20 minute) individual training sessions. Upon 
satisfactory completion of training, a GP writes a prescription for each program participant. 
Service staff take the prescriptions to a local pharmacy and return to the service with the 
naloxone. Program participants are then provided with a ‘naloxone kit’. This contains 
naloxone in the form of five 400 ug/mL pre-filled syringes (Minijets®), needles for 
intramuscular injection, alcohol swabs, gloves to minimise potential blood exposure during 
administration, a face-shield mask to use for mouth-to-mouth resuscitation if necessary and 
an information sheet on resuscitation and naloxone administration.  
 
The second Victorian THN strategy is the Community Overdose Prevention and Education 
(COPE) program led by Penington Institute. This program conducts group sessions to train 
alcohol and other drug (AOD) workers and other community workers (e.g., housing, welfare) 
in the use of naloxone in order that they may then provide this training to people who use 
opioids. The COPE website also provides written materials for GPs and pharmacists. These 
detail procedures for conducting brief interventions on overdose recognition, response and 
reversal with naloxone (www.copeaustralia.com.au). The COPE strategy does not involve 
direct provision of THN.  
 
Reports are beginning to emerge on the feasibility and successful implementation of THN 
programs for people who use opioids in the Australian Capital Territory, New South Wales 
and Western Australia (Chronister et al., 2015; Lancaster and Ritter, 2014; Lenton et al., 
2015; Olsen et al., 2015). Overall, however, the literature on THN in Australia, including key 
issues for expanding THN availability, remains scant. In this article, we focus on the 
Victorian peer-based THN direct distribution strategy led by HRV. This article contributes to 
the literature by describing and analysing the perceptions and experiences of service 
providers regarding provision of THN to people who use opioids in Victoria. In particular, we 
describe the benefits and risks of THN discussed by service providers, and their perceptions 
of barriers to expanding the availability of THN. 
 
Method 
Data for this article are drawn from an independent evaluation accompanying the HRV-led 
THN initiatives. The evaluation was conducted by the first and third authors (at Victoria 
University and Burnet Institute, respectively). The evaluation comprised: pre- and post-
training assessment of opioid consumer program participants’ knowledge regarding overdose 
recognition and response and naloxone administration; structured follow-up interviews with 
program participants; and brief semi-structured qualitative interviews with service providers. 
Here we report on the service provider interview data. Approval for the evaluation study was 
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granted by the Alfred Hospital Human Ethics Research Committee. All participants provided 
written consent to be involved in the study.  
 
Service providers were selected using a purposive recruitment strategy involving a 
combination of selection of critical cases and participant selection aiming for maximum 
variation (Marshall, 1996). Critical cases were participants with special expertise, in this case 
the co-ordinating staff member at every service facilitating the HRV-led initiatives (n=8). A 
maximum variation strategy selects a distributed range of participants to gather a range of 
views on an issue. In this case, service providers whose work brings them into contact with 
people who use opioids were approached from a range of service types and occupational roles 
– AOD treatment workers, crisis accommodation services, outreach health services, 
pharmacotherapy (opiate substitution) program. All service providers who were approached 
agreed to participate in the study. 
 
Interviews were conducted between December 2014 and July 2015. The majority of service 
providers worked in urban and peri-urban areas of Melbourne, the capital city of Victoria. 
Two participants worked in regional areas outside the city. Interviews were conducted by a 
Victoria University research assistant either over the telephone or in person at the 
participant’s place of work. They ranged in length from 20-45 minutes. All service providers 
were asked if they were aware of the THN initiatives in Victoria and then asked for their 
views on THN provision to people who use opioids. They were also asked to describe the 
benefits and risks of providing THN to people who use opioids, and to describe (or consider) 
the impact on their service or organisation of expanding the availability of naloxone. Service 
providers involved in the HRV peer-to-peer THN initiatives were additionally asked to 
describe their experiences implementing THN and asked whether they had experienced any 
unintended consequences from implementing these programs. All interviews were digitally 
recorded and professionally transcribed. Transcripts were entered into QSR International’s 
NVivo 10 for organisation and analysis. Transcripts were read and systematically compared 
and coded to identify key analytic categories and themes. Basic content analysis was 
performed, guided by the broad interest areas of benefits, risks, and barriers (Silverman, 
2011). Pseudonyms have been used to preserve participant anonymity. Some interview 
extracts have been edited for clarity or in order to combine related comments made at 
different times during the interview. 
 
Findings 
Fifteen service providers were interviewed, eight of whom were directly involved in the 













Laura 49 Yes 
Patti 37 Yes 
Lydia 48 Yes 
Debbie 28 Yes 
Joe 40 Yes 
Tom 34 Yes 
Richard 48 Yes 
Joey 41 Yes 
Suzy 28 No 
Joan 38 No 
Poly 51 No 
Ari 57 No 
Donita 54 No 
Sid 69 No 
Dave 52 No 
 




At the time of interview, individual services’, and consequently study participants’, 
experience with THN distribution ranged from three to 20 months. Three of the agencies 
running THN programs also provided individual naloxone training to people who use opioids 
in addition to the HRV-led training. Two participants from these agencies had undertaken the 
COPE program training (overdose recognition and response and naloxone administration) 
and were training people who use opioids. These service providers had mechanisms in place 
to allow immediate prescription and dispensing of naloxone to trainees. Among the seven 
service providers not involved in THN programs, two had also undertaken the COPE training 
but were yet to provide training to any people who used opioids. Neither of these participants 
had established prescribing or dispensing mechanisms to enable direct provision of naloxone. 
Participants worked at a range of health and welfare agencies, comprising specialist drug-
related primary health care, needle and syringe programs (NSPs), Victoria’s drug user 
organisation, as well as community health, crisis accommodation and youth services. Their 
occupational roles comprised community development, NSP work, health work, general 




Statements about THN distribution to people who use opioids were universally positive, with 
service providers describing THN as an important initiative and a valuable addition to harm 
reduction strategies. Several services providers said that naloxone should be made more 
broadly available, including to people on pharmacotherapy (opioid substitution treatment), 
people being discharged from detoxification and residential rehabilitation services or released 
from prison, as well as to the partners, family and friends of people who use opioids. Richard 
(THN program provider), for instance, stated, ‘it should be a standardised part of basic first 
aid training’. Participants described several benefits of providing people who use opioids 
with THN, and identified few significant risks or unintended consequences. A number of 
potential barriers to expanding the availability of naloxone were also discussed. While not 
every participant noted or discussed each and every benefit, risk or barrier identified in 
analysis, none of the participants expressed disagreement or contrary views regarding the 
benefits, risks and barriers reported here. There were no differences between the views of 
service providers who were, and those who were not, involved with THN distribution. We 
begin with discussion of the benefits of THN. These have been separated into direct and 
indirect benefits. 
 
Benefits of THN 
The key direct benefit of THN described by service providers was the potential reduction in 
opioid overdose-related deaths and other harms. All participants described the potential for 
THN to ‘save lives’ and reduce opioid overdose deaths. Several of the service providers 
involved in THN programs also described feedback they had received from program 
participants regarding opioid overdose reversals using naloxone. As Debbie, a service 
provider involved with the THN program, notes: 
I think we’ve given out about 190 individual scripts, almost 200 individual scripts 
[…] [and] we’ve had, anecdotally, probably about ten or fifteen per cent of people 
saying that they have used it. 
 
Other participants said that providing naloxone to people who use opioids had the potential to 
reduce other harms associated with opioid overdose, such as acquired brain injury or 
compartment syndrome, as well as indirect harms. Suzy explains:  
something that I see pretty regularly, which is really sad […] is that a lot of them have 
acquired brain injuries and things from having a lack of oxygen to their brain when 
they’ve been in overdose. So it’s not even just about the deaths, is it. It’s about all of 
the other impacts of overdose.  
 
The key indirect benefit of THN described by service providers was its empowering effect on 
people who use opioids, who can use the naloxone in the event of an opioid overdose 
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emergency. Several participants explicitly described THN as ‘empowering’ while others 
employed words and phrases synonymous with concepts of empowerment. The Oxford 
Dictionary (Stevenson, 2010) defines empowerment as both granting people the ‘authority or 
power […] to do something’ or as ‘the process of becoming stronger and more confident, 
especially in controlling one’s life and claiming one’s rights’. Participants invoked both 
senses of empowerment. For example, Debbie describes THN as giving people who use 
opioids the power to act:  
it’s been really great in terms of, I guess, people having just … being empowered to 
take action themselves and having the resources to be able to respond to their own and 
their friends and their peers’ overdoses. 
She also discusses the second sense of empowerment:  
the benefits are huge in terms of people feeling much more in control of their drug 
use, and much more able to respond to emergencies around them. And not just being 
at the will and at the hands of the professionals or the medical world and waiting for 
ambos [ambulance paramedics] or waiting for GPs to respond to these things […] I 
just think it’s great in terms of a shift in self-determination and being able to control 
and have the resources to be able to be safe. 
 
Comments made by other service providers similarly referenced the second sense of 
empowerment. For instance, in the quotations below, Suzy highlights the ways THN 
programs increase people’s confidence and self-esteem and Richard anticipates an increase in 
consumer activism to access naloxone. 
 
[THN is] really good for their [clients’] confidence and their self-esteem [It indicates] 
that we’re actually looking to them and recognising that they’re, kind of, experts. 
(Suzy) 
 
As the training rolls out […] then hopefully we’ll start to see that cultural shift, where 
people expect and demand naloxone. So it’s not us [services] pushing but, rather, the 
clients demanding. (Richard) 
 
Participants involved in THN provision also described other indirect benefits of THN 
initiatives. Several observed that the program had enhanced service provision by adding a 
useful service they could offer clients. Others said the program had served to increase and 
enhance their engagement with clients. 
 
Risks of THN  
When asked to describe any risks associated with THN, several participants raised the 
possibility that people might increase consumption of opioids because naloxone would 
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provide a ‘safety net’ in the event of overdose. However, this concern was raised only to 
refute it. For example, as Tom (THN program provider) explains: 
I know there’s concerns about, if you give people naloxone, will they use more than 
they would otherwise? I don’t know that any of the evaluations or research so far have 
really borne that out. I think it’s a bit contrary to generally [the consumer’s] aim, 
which is to get stoned [intoxicated], not to be administered with naloxone. So it 
doesn’t really … I know it’s a concern, but I don’t know that it, A, really makes sense 
and, B, is borne out.  
 
Some participants raised the issue of violence or abuse on administration of naloxone, 
suggesting that any aggression was related to the volume of naloxone administered – higher 
doses could put consumers into precipitated withdrawal – and that the HRV-led THN 
program recommended lower doses so as to minimise this possibility. A few also remarked 
that any aggression encountered by emergency workers could be explained by consumer fear 
and anxiety on returning to consciousness while surrounded by people in uniforms. These 
participants considered such anxiety (and any associated aggression) far less likely to occur 
when people were revived in familiar environments in the company of people they knew. 
Suzy noted aggression as a theoretical risk but qualified her response with the remark: ‘I 
don’t know how much of a myth this is’. One participant mentioned a concern that people 
who use opioids would not have the capacity to recognise overdose. As with the concern over 
increased consumption, this was dismissed as neither borne out by her experience nor by 
research.  
 
Other risks were also discussed. Several participants noted the shorter half-life of naloxone in 
comparison with opioids such as heroin and therefore a risk that overdose would recur once 
the naloxone had worn off. All of these participants argued that this risk could be minimised 
through appropriate education and training, and Tom further pointed out that it is also present 
when people are revived by paramedics. Some participants noted the risk of infection or 
blood-borne virus transmission via injection of naloxone. Others raised the issue of 
precipitated withdrawal (unintentional or intentional) and the concomitant physical distress 
and suffering people revived with naloxone might experience. As with the risk of overdose 
recurrence, the risks of blood-borne virus transmission or precipitated withdrawal were seen 
as reducible through education and training. No adverse or unintended consequences of 
implementing THN were described by the eight service providers directly involved in THN 
provision.  
 
In sum, service providers discussed some risks associated with THN. All were dismissed, 
however, as ‘myths’, ‘not borne out’ by the evidence or experience, or minor in comparison 
to the potential gains of reducing overdose harms. As Debbie points out: 
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And most of those people, that community [THN program participants], are people 
that we know fairly regularly. So I guess those sorts of myths or concerns have been 
debunked in just this process over the last twelve months, fourteen months. 
Making a different point, Sid offers a cost-benefit analysis, remarking, ‘if someone’s going to 
die, I think they’re small risks’. 
 
Barriers to expanding availability of THN  
Service providers identified several issues likely to act as barriers to expanding the 
availability of naloxone. These comprised cost, availability of prescribers, regulations and 
scheduling, legal concerns, burden on services, and stigma associated with heroin use and 
injecting drug use. Below we separate these for presentation purposes, but participants 
described them as intertwined such that addressing one barrier could exacerbate the effects of 
another barrier.  
 
Price was identified as a significant potential barrier to increasing the availability of naloxone 
to people who use opioids. During our data collection period naloxone was only available 
through prescription and subsidised under Australia’s Pharmaceutical Benefits Scheme 
(PBS). Under the PBS, the price for up to five 400 ug/mL naloxone Minijets® is $36.10. This 
reduces to approximately $6 for welfare recipients in possession of a government concession 
card entitling them to health care (and other) concessions (Lenton et al., 2015). However, as 
noted by some participants, even this small sum can be prohibitive for some people who use 
opioids who may rely on welfare benefits for income. These participants also drew attention 
to the added financial burden for welfare recipients who are on pharmacotherapy. The 
following comments from Ari and Laura provide examples: 
six bucks [dollars] to somebody who is using drugs, on Centrelink [government 
welfare agency] and has a whole other range of bills, six dollars is a lot. I mean, you 
know, that’s your dose of methadone or bupe [buprenorphine] for a day. (Ari) 
 
we run [a service], with people wanting money for methadone and stuff. Every day 
they’re ringing up for just five bucks to, you know, get their dose so they’re not 
hanging [in withdrawal]. So I just can’t see people putting their hand in their pocket to 
pay for naloxone. (Laura) 
 
Service providers involved in the HRV-led THN programs explained that in recognition of 
the potentially prohibitive financial burden for people who use opioids, the costs of the 
Minijets® were borne by the agency, or sometimes by HRV. Participants also described other 
costs associated with the HRV-led THN programs. Ari’s comment is typical: 
Yeah, so there’s the financial thing, and it’s like staff coverage and all that, but also 
there’s a thing that HRV give out, this little pack […] and there’s things like a mask 
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[resuscitation face-shield mask] […] gloves, and a little pack to carry it all in. I mean, 
that’s a financial burden that we can’t actually do. 
 
As described earlier, all participants in the THN programs led by HRV receive a ‘naloxone 
kit’ – a pencil case containing the THN Minijets®, needles, swabs, gloves and face-shield 
mask. The needles required for intramuscular injection do not incur costs for agencies as they 
are available through the Victorian needle and syringe program. However, according to the 
HRV peer educator, costs of the other equipment in the naloxone kit, and the pencil case 
itself, are borne by HRV.  
 
Ari’s comment also makes clear that hosting the HRV-led naloxone training carries a further 
financial cost associated with staffing. Most agencies needed to roster an additional staff 
member on THN training days. Participants discussed the challenges of finding the financial 
resources to cover these costs for the small-scale THN initiatives currently running, given the 
lack of specific THN ‘budget’ (Patti) or ‘direct funding’ (Richard). Several service providers 
stated that in the absence of specific funding, while training of opioid consumer clients in the 
use of naloxone would remain feasible, these costs could well become prohibitive for further 
scale-up of direct naloxone provision. 
 
Limited availability of medical practitioners and current regulations and scheduling were also 
identified as potential barriers to expanding the availability of THN. Each of the services 
currently running the HRV-led THN programs employ GPs who are able (and willing) to 
prescribe naloxone. However, as participants noted, these GPs are available only for a limited 
time each week. This means missed opportunities when consumers request naloxone when a 
doctor is not on site. Some service providers involved in the HRV-led THN programs also 
commented that naloxone prescribing added to the workload of their already over-burdened 
GPs. Others said that efforts to increase uptake of naloxone prescribing among community or 
‘mainstream’ GPs were needed. As Debbie explains: 
people will come in five or six times asking for it and they’ve just always seemed to 
come in on a time when there’s no GP there, [so we’re] always missing that 
opportunity to be able to provide it [naloxone] then and there on the spot […] we have 
[GPs with us for a] limited time [and they] are also spending moments of their time 
with people that really could be accessing it in [the] mainstream but it’s just that they 
don’t know who to go to or GPs aren’t aware or … that’s the biggest next step, is the 
GPs in the community getting on board. 
Likewise, Richard comments: 
 [a] doctor’s time is very short and valuable and the time when a doctor is available 
and the time when a person’s walking in the door and saying, ‘I want naloxone’, may 
not correlate. The doctors that work here, have very high caseloads […] If we find it a 
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challenge here, and we’ve got doctors on board, then I imagine it would only be even 
worse for services that don’t have GPs on side. How on earth do they make sure that 
the naloxone gets into the hand of the person who’s rocking up asking for it? So 
addressing the fact that it needs to be prescription only, I think that’s a pretty big thing 
that we need to get across really quickly. Really quickly. 
 
In relation to these barriers, several participants suggested re-scheduling naloxone to allow 
the drug to be obtained without a prescription over the counter at pharmacies. They also 
acknowledged, however, that re-scheduling naloxone might affect its PBS listing and 
associated subsidy, which could then increase its price. Other participants suggested retaining 
naloxone under its current schedule but loosening the regulations around prescribing in order 
to make naloxone available to partners and family members of people who use opioids, to 
health and welfare workers and to first responders such as the fire brigade.  
 
Legal concerns around THN were also mentioned. Issues raised here were doctors’ concerns 
around the medico-legal aspects of prescribing naloxone and the legal implications of 
administering naloxone to someone other than the person to whom it was prescribed. Service 
providers who raised the latter concern did also comment that ‘Good Samaritan laws’ would 
likely provide protection. Good Samaritan civil liability legislation exists across Australian 
jurisdictions. Such legislation holds that a person who acts in good faith to render assistance 
in a medical emergency without expectation of payment is not liable for any damage caused 
by their act.  
 
Logistical demands and challenges were also described by participants involved with THN 
programs. These included promotion of training workshops and telephone contact reminders 
to clients to ensure attendance, patient record administrative tasks, ensuring the local 
pharmacy had naloxone in stock, rostering sufficient staff and coordinating the GP. In the 
light of such challenges, participants discussed the importance and necessity of collaboration 
and partnerships for the successful implementation of THN programs in the current 
regulatory context. 
 
Stigma associated with heroin use and injecting was also identified as posing a barrier to 
expanding availability and uptake of THN. This stigma was perceived to constrain the 
willingness of community GPs to prescribe naloxone, and people who use opioids’ 
willingness to request naloxone from community GPs or pharmacotherapy (opioid 
substitution) prescribers. Some participants also suggested, given the current naloxone 
Minijet® delivery system which requires use of a needle, that stigma associated with 
injecting drug use and needles may pose a barrier to uptake and administration of THN by 





Service providers in the Australian evaluation study described here were overwhelmingly 
supportive of THN provision to people who use opioids. Both direct and indirect benefits of 
THN were described. These included potential reductions in overdose-related harms, 
enhanced service provision and important empowerment effects of providing people who use 
opioids with the resources to respond in overdose emergency situations. In this respect, our 
findings are consistent with the small body of international literature on the perspectives of 
service providers involved with THN distribution programs (Banjo et al., 2014).  
 
The international literature on attitudes to THN among health professionals not directly 
involved with such programs (or where levels of involvement are not detailed) shows greater 
ambivalence to THN than was seen among the service providers in this study who were not 
directly involved with THN provision (Binswanger et al., 2015; Green et al., 2014; Hill and 
McAuley, 2012; Matheson et al., 2014; Mueller et al., 2015). Importantly, ours was a study of 
service providers who have experience providing services to people who use or inject drugs. 
This familarity may account for their awareness and support for THN in contrast to other 
health professionals described in the literature. Some service providers did discuss 
‘objections’ to THN previously identified in the literature: moral hazard as THN would 
encourage increased opioid consumption; that lay people, particularly those who use opioids, 
would not have the capacity to recognise and respond to an opioid overdose; and that people 
revived by naloxone may become abusive or violent (Bazazi et al., 2010; Mueller et al., 
2015). These concerns were raised only in order to refute them. Overall, participants in this 
study described no significant risks associated with THN. In general, participants supported 
the expansion of THN distribution initiatives to enhance Australia’s response to opioid 
overdose. Importantly, service providers directly involved in THN programs described no 
adverse or unintended consequences of providing people who use opioids with naloxone.  
 
However, several potential barriers to scale-up and expansion were described. Costs 
associated with THN were identified as a potentially significant impediment to expanded 
availability. Although naloxone is relatively inexpensive in Australia, in particular for 
concession card holders ($6), service providers expressed concern that price would be a 
barrier to uptake of THN if people who use opioids were required to bear this cost 
themselves. To our knowledge, the extent to which this would constitute a barrier has not 
been investigated because existing THN programs all provide naloxone to participants at no 
cost (e.g., Banjo et al., 2014; Chronister et al., 2015; McAuley et al., 2012; Olsen et al., 2015; 
Walley et al., 2013). However, given the evidence that similarly priced opioid 
pharmacotherapy fees constitute a major barrier to pharmacotherapy treatment access and 
retention in Australia (Chalmers and Ritter, 2012), it is not unreasonable to suppose that price 
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may pose a significant barrier to uptake of THN if participants were required to bear the cost 
themselves. The organisations running THN programs in this study were able to redirect 
some existing service funds in order to provide naloxone to program participants at no cost. 
As service providers explained, this was sustainable for the small-scale programs described in 
this study. However, in the absence of specific THN funding, costs could well become 
prohibitive for further scale-up. In particular, cost issues need to be addressed in order to 
ensure that people on low incomes and organisations providing THN programs continue to be 
able to access and distribute naloxone (Lenton et al., 2015).  
 
Existing regulations and scheduling of naloxone were also described as impediments to THN 
expansion. During the study period, naloxone was scheduled as a prescription-only medicine, 
but this will change in early 2016. As our participants noted, prescription means that the 
limited availability of medical practitioners trained and willing to prescribe naloxone also 
remains a barrier to expanding its availability. Although the scheduling change potentially 
addresses this barrier, the over the counter co-scheduling proposed means that pharmacists 
will be needed to provide the drug to participants who obtain it over the counter. The 
impediments and challenges attendant on pharmacists selling naloxone similarly require 
investigation. Moreover, consumers are likely to pay much less for naloxone obtained on 
prescription than over the counter, meaning prescription will still be important for many 
service users.  
 
Service provider accounts also shed light on additional elements limiting availability of 
prescribers here. Participants suggested that there was limited knowledge of naloxone, 
concerns over medico-legal implications of prescribing and uncertainty relating to protections 
provided by Good Samaritan laws among medical practitioners. Service providers also 
suggested that the willingness of medical practitioners to prescribe may be constrained by 
stigma associated with heroin use, injecting drug use and people who inject drugs. A similar 
dynamic has been noted in relation to expanding needle and syringe programs (Treloar et al., 
2015). Stigma as an impediment to THN is also suggested in some international literature 
(Beletsky, et al., 2006; Matheson et al, 2014; Mueller et al., 2015). However, the role of 
stigma in shaping uptake and diffusion of THN has not been explored in-depth and warrants 
further investigation. Expanding the number of medical practitioners prescribing naloxone is 
one issue the Victorian COPE THN initiative aims to address. COPE strategies include 
raising awareness and increasing knowledge of THN among health professionals – 
pharmacists, GPs and Emergency Services. The COPE website includes ‘fact sheets’ on 
prescription and administration of naloxone and guides for the incorporation of THN into a 
medical practice or pharmacy. However, questions remain as to the uptake of this information 
by health professionals, and further research is needed to better understand their knowledge 




Given the stigma associated with injecting drug use and needles, service providers also 
suggested that the naloxone delivery system which requires use of a needle may pose a 
barrier to uptake of THN by people unfamiliar with injecting. Naloxone administration via an 
intranasal delivery system might address this issue. While several THN programs in the US 
have been using intranasal naloxone since 2006, further research is required to develop and 
validate this route of administration (Strang et al., 2014). Moreover, naloxone is not currently 
approved in Australia for intranasal use.  
 
Considerable logistical challenges associated with running THN programs were also 
described by participants. Implicit in these descriptions was the considerable energy, 
enthusiasm and commitment of the service providers involved in setting up and continuing to 
facilitate THN to people who use opioids, because they demonstrated a willingness to engage 
with the HRV-led THN program in spite of the challenges. Researchers reporting on THN in 
other Australian jurisdictions have similarly observed that provision of THN to people who 
use opioids relies on goodwill, the energy and enthusiasm of THN advocates and supporters 
and strong partnership relationships between stakeholders – people who use opioids, peer-
based organisations, health and community workers, GPs and pharmacists (Lancaster and 
Ritter, 2015; Lenton et al., 2015). In Australia, THN provision has been confined primarily to 
people who inject drugs. These initiatives have been facilitated by existing structures and a 
supportive experienced workforce with a harm reduction background (Lancaster and Ritter, 
2015; Lenton et al., 2015). Other people who use opioids, such as people on opioid 
substitution therapy and the substantial numbers of people who are prescribed opioids for 
pain management would also likely benefit from access to naloxone (Roxburgh et al., 2011; 
Strang et al., 2014). Research suggests provision of THN to people on methadone is feasible 
(Chronister et al., 2015; Walley et al., 2013). However, literature on the views of THN 
among medical prescribers (of methadone and opioids for pain management) is scant and 
questions remain regarding the potential challenges and barriers to THN provision to other 
people who use opioids who may benefit.  
 
Conclusions 
Expanding the availability of naloxone is a key component of strategies to reduce harms 
associated with opioid overdose (Strang et al., 2014; WHO, 2014). A substantial proportion 
of people who use opioids report witnessing an opioid overdose. Providing this group with 
naloxone, and therefore with the means to reverse the overdose, is a practical technological 
intervention with significant potential to reduce harm. Research indicates that THN programs 
are safe and can result in successful opioid overdose reversals (Clark et al., 2014; Giglio et 
al., 2015) and there is recent evidence demonstrating that THN programs reduce opioid-
related deaths at a population level (Bird et al. 2015). Our exploratory study of the views and 
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experiences of service providers involved in the first THN program in Victoria contributes to 
the evidence base for take-home naloxone in Australia. By highlighting service provider 
willingness and understanding of the issues related to THN programs, our study adds to 
growing evidence of their feasibility for people who use opioids in Australia (Chronister et 
al., 2015; Lancaster and Ritter, 2014; Lenton et al., 2015; Olsen et al., 2015). The study 
provides Australian evidence of the successful processes of implementing and incorporating  
peer-to-peer THN delivery within a range of specialist drug primary health services and 
needle syringe programs. Our article also adds to the literature on key issues for THN 
provision to people who use opioids in Australia. It describes implementation issues 
experienced within the particular circumstances obtaining in Australia – particular policies, 
laws, service structures and attitudes to drug use and drug users. Some of these circumstances 
are specific to Australia while others will be shared with other jurisdictions. As such, the 
study contributes to international literature on THN and its delivery in different settings. 
However, it has also highlighted several issues requiring further investigation in order to 
better understand the implications of, and impediments to, expanding naloxone availability in 
Australia.  
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